Germany’s Hidden Crisis: The €64.4 Billion Annual Cost of Long COVID and ME/CFS
Berlin, Germany — On a quiet Monday in April 2026, the full weight of a silent epidemic finally landed on Germany’s balance sheets. A new study, published by the ME/CFS Research Foundation and Risklayer, reveals that Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) now cost German society €64.4 billion annually—equivalent to 1.44% of the country’s gross domestic product. The figure, which has climbed steadily since the pandemic began, underscores a crisis that experts warn will not resolve itself without urgent intervention.
“Von allein wird dieses Problem nicht verschwinden,” (“This problem will not disappear on its own”), Jörg Heydecke, a spokesperson for the ME/CFS Research Foundation, told researchers. His words, published in the study’s accompanying materials, capture the grim reality facing over 1.4 million Germans living with these debilitating conditions. For a nation still grappling with the aftermath of COVID-19, the findings are a wake-up call: the economic and human toll of post-viral illnesses is not just persisting—it’s growing.
The Numbers: A Breakdown of the €64.4 Billion Burden
The study, which updates a 2025 report, breaks down the societal costs into three categories: direct medical expenses, lost productivity, and informal caregiving. The largest share—€38.2 billion—stems from lost productivity, as patients are unable to work or must reduce their hours. Direct medical costs, including hospitalizations, medications, and outpatient care, account for €15.6 billion, while informal caregiving by family members adds another €10.6 billion. These figures do not include the intangible costs of suffering, such as reduced quality of life or the emotional strain on families.
Since 2020, the cumulative societal cost of Long COVID and ME/CFS in Germany has reached €318.8 billion, according to the study. The modeling, which uses established disaster-impact assessment methods, is available as open-source data for public scrutiny. The report’s authors emphasize that their estimates are conservative, as they do not account for indirect costs like mental health support or long-term disability benefits.
Who Is Affected? The Human Cost Behind the Numbers
As of December 2025, Germany is home to 1.414 million people living with Long COVID or ME/CFS. Of these, 757,000 have Long COVID—a slight decrease from 2024—while 657,000 have ME/CFS, a condition often triggered by viral infections. The overlap between the two conditions is significant, with many ME/CFS patients initially diagnosed with Long COVID before their symptoms persisted beyond the typical recovery period.
The personal stories behind these statistics are harrowing. Many patients, including young adults and children, are unable to attend school or work. Severe cases leave individuals bedridden, hypersensitive to light and sound, and dependent on caregivers for basic tasks like eating or bathing. The study highlights the disproportionate burden on women, who make up roughly 70% of ME/CFS patients, and the strain on families who often become full-time caregivers without formal support.
“The lack of effective treatments is not just a medical failure—it’s a societal one,” said Dr. Carmen Scheibenbogen, a leading immunologist at Charité – Universitätsmedizin Berlin and a co-author of the study. “These conditions are not rare. They are a public health emergency, and we are failing the people who need us most.”
Why the Costs Keep Rising
The €1.3 billion increase in annual costs from 2024 to 2025 reflects a troubling trend: while acute COVID-19 cases have declined, the long-term consequences of the virus are becoming more entrenched. ME/CFS, in particular, is a chronic condition with no cure, and its prevalence has risen as more people experience post-viral symptoms that fail to resolve. The study’s authors warn that without significant investment in biomedical research, the economic and human costs will continue to escalate.
One key driver of the rising costs is the lack of early intervention. Many patients report years-long diagnostic odysseys, during which their symptoms are dismissed or misattributed to psychological factors. By the time they receive a diagnosis, their condition has often worsened, leading to higher medical costs and greater productivity losses. The study estimates that up to 25% of ME/CFS patients are completely bedridden, a figure that has remained stubbornly high since the pandemic began.
Germany’s Response: A National Decade Against Post-Infectious Illnesses
In late 2025, the German Federal Ministry of Education and Research (BMBF) announced the “Nationale Dekade gegen Postinfektiöse Erkrankungen” (“National Decade Against Post-Infectious Illnesses”), a 10-year initiative to combat Long COVID, ME/CFS, and other post-viral conditions. The program, which runs from 2026 to 2035, allocates €500 million to research, with a focus on identifying biomarkers, developing treatments, and improving diagnostic tools.
“This is a critical step, but it’s only the beginning,” said Heydecke. “The longer we wait to invest in research, the higher the costs will climb. We need a coordinated effort across medicine, policy, and society to address this crisis.”
The initiative includes funding for clinical trials, the establishment of specialized treatment centers, and public awareness campaigns to reduce stigma. But, advocates warn that the €500 million allocation—while significant—may not be enough to address the scale of the problem. For comparison, the annual societal cost of Long COVID and ME/CFS in Germany is now higher than the country’s entire annual spending on education (€58 billion in 2025).
The Global Context: A Crisis Without Borders
Germany is not alone in facing this challenge. The United Kingdom, the United States, and other high-income countries have reported similar trends, with Long COVID and ME/CFS emerging as major public health concerns. In the U.S., the Centers for Disease Control and Prevention (CDC) estimates that up to 2.5 million Americans have ME/CFS, while Long COVID has affected an estimated 17 million adults. The economic impact in the U.S. Is equally staggering, with one study estimating annual productivity losses of $185 billion.
Despite the growing recognition of these conditions, global research funding remains disproportionately low. A 2023 analysis by the #MEAction Network found that ME/CFS receives less than 0.1% of global biomedical research funding, despite its significant burden on society. Long COVID, while better funded, still lags behind other post-viral conditions like HIV/AIDS or Lyme disease.
What’s Next? A Call for Urgent Action
The ME/CFS Research Foundation and Risklayer study serves as a stark reminder that the pandemic’s legacy is far from over. With 1.4 million Germans already affected—and millions more at risk—the need for action is urgent. Key priorities include:
- Biomedical Research: Identifying the root causes of Long COVID and ME/CFS, including potential viral persistence, immune dysfunction, and metabolic abnormalities.
- Early Diagnosis: Developing rapid diagnostic tools to reduce the years-long delays many patients face in receiving a correct diagnosis.
- Treatment Development: Expanding clinical trials for potential therapies, including antivirals, immunomodulators, and metabolic interventions.
- Workplace and Education Support: Creating flexible policies to accommodate patients who are unable to work or attend school full-time.
- Public Awareness: Combating stigma and misinformation about these conditions, which are often dismissed as “psychological” or “imagined.”
For patients and their families, the path forward is fraught with uncertainty. Many describe feeling abandoned by a healthcare system that has yet to catch up with the scale of the crisis. “We are not asking for miracles,” said one patient, who wished to remain anonymous. “We are asking for research, for recognition, and for a chance to live our lives without being treated like we’re invisible.”
Key Takeaways
- €64.4 Billion Annual Cost: Long COVID and ME/CFS cost German society €64.4 billion in 2025, up from €63.1 billion in 2024, representing 1.44% of GDP.
- 1.4 Million Affected: Over 1.4 million Germans live with Long COVID or ME/CFS, with 757,000 cases of Long COVID and 657,000 cases of ME/CFS as of December 2025.
- Productivity Losses Dominate: Lost productivity accounts for €38.2 billion of the total costs, followed by direct medical expenses (€15.6 billion) and informal caregiving (€10.6 billion).
- National Response: Germany’s “National Decade Against Post-Infectious Illnesses” allocates €500 million to research and treatment from 2026 to 2035.
- Global Challenge: Similar trends are observed in the U.S., U.K., and other countries, with Long COVID and ME/CFS emerging as major public health concerns.
- Urgent Need for Research: Experts warn that without significant investment in biomedical research, the economic and human costs will continue to rise.
What Happens Next?
The next major milestone in Germany’s response to Long COVID and ME/CFS will be the launch of the first round of research grants under the “National Decade Against Post-Infectious Illnesses” initiative, expected in late 2026. The BMBF has also announced plans to establish a national registry for post-viral conditions, which will help track the prevalence and progression of these illnesses.
For patients and advocates, the hope is that these steps will mark the beginning of a sustained effort to address a crisis that has, for too long, been overlooked. As Heydecke set it: “The time for action is now. The cost of inaction is simply too high.”
What are your thoughts on Germany’s response to Long COVID and ME/CFS? Do you or someone you know live with these conditions? Share your experiences in the comments below, and help us raise awareness by sharing this article with your network.